Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022PRNewsWire • 11/02/22
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia StudyPRNewsWire • 08/30/22
Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022PRNewsWire • 07/28/22
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid CongressPRNewsWire • 06/10/22
Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO MeetingBenzinga • 06/06/22
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)PRNewsWire • 06/04/22
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)PRNewsWire • 05/12/22
Curis Inc.'s (CRIS) CEO Jim Dentzer on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Down 31.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Curis (CRIS)Zacks Investment Research • 05/04/22
Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022PRNewsWire • 04/28/22